Scholarlink

Objectives <p>We aimed to show that spectral computed tomography (CT) can identify different patterns of airway wall thickening and contrast enhancement in lung-healthy controls, coronavirus disease 2019 (COVID-19), and non-COVID-19 pneumonia patients, reflecting airway inflammation in both pneumonia subtypes and airway neovascularization in COVID-19.</p> Materials and methods <p>331 subjects (age 58.9 ± 17.2 years) with 218 arterial and 113 venous phase spectral CT acquisitions were retrospectively recruited: 119 lung-healthy controls, 45 with COVID-19 and 167 with non-COVID-19 pneumonia. Scientific software was used for segmenting the airway tree. Wall thickness (WT<sub>5-10</sub>) and the difference in median maximum airway wall attenuation (slope of the spectral attenuation curve) between 40 keV and 100 keV display energy were calculated and aggregated for subsegmental airway generations 5–10 (λHU<sub>5-10</sub>). Descriptive statistics, correlations, <i>t</i>-tests, and ANOVA analyses were performed.</p> Results <p>Arterial phase WT<sub>5-10</sub> was similarly increased in COVID-19 (1.70 ± 0.44 mm) and non-COVID-19 (1.64 ± 0.53 mm) pneumonia compared to controls (1.18 ± 0.34 mm, <i>p</i> &lt; 0.001). Arterial phase λHU<sub>5-10</sub> was significantly higher in patients with COVID-19 pneumonia (3.09 ± 2.27 HU/keV) than in non-COVID-19 pneumonia (2.18 ± 1.54 HU/keV, <i>p</i> &lt; 0.01) and lung-healthy controls (2.06 ± 1.11 HU/keV, <i>p</i> &lt; 0.01).</p> Conclusion <p>Spectral CT shows significant differences in segmental wall thickness and airway contrast enhancement between COVID-19 and non-COVID-19 pneumonia and lung-healthy controls. Airway contrast enhancement may be a feasible measure to detect airway inflammation in pneumonia and neovascularization in COVID-19 pneumonia.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>Is spectral CT airway contrast enhancement a feasible quantitative method to detect airway inflammation or neovascularisation?</i></p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>Spectral CT shows significant differences in segmental wall thickness and airway contrast enhancement between COVID-19 and non-COVID-19 pneumonia, and lung-healthy controls.</i></p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>Spectral CT can be used to assess inflammatory airway diseases such as cystic fibrosis, COPD, asthma and bronchiectasis.</i></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quantitative spectral computed tomography detects different patterns of airway wall thickening and contrast enhancement in infective lung disease: a feasibility study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月19日

查看全文
  • Philip Konietzke,
  • Johanna Thomä,
  • Oliver Weinheimer,
  • Thuy D. Do,
  • Willi L. Wagner,
  • Arndt L. Bodenberger,
  • Wolfram Stiller,
  • Tim F. Weber,
  • Claus P. Heußel,
  • Hans-Ulrich Kauczor,
  • Mark O. Wielpütz

摘要

Objectives

We aimed to show that spectral computed tomography (CT) can identify different patterns of airway wall thickening and contrast enhancement in lung-healthy controls, coronavirus disease 2019 (COVID-19), and non-COVID-19 pneumonia patients, reflecting airway inflammation in both pneumonia subtypes and airway neovascularization in COVID-19.

Materials and methods

331 subjects (age 58.9 ± 17.2 years) with 218 arterial and 113 venous phase spectral CT acquisitions were retrospectively recruited: 119 lung-healthy controls, 45 with COVID-19 and 167 with non-COVID-19 pneumonia. Scientific software was used for segmenting the airway tree. Wall thickness (WT5-10) and the difference in median maximum airway wall attenuation (slope of the spectral attenuation curve) between 40 keV and 100 keV display energy were calculated and aggregated for subsegmental airway generations 5–10 (λHU5-10). Descriptive statistics, correlations, t-tests, and ANOVA analyses were performed.

Results

Arterial phase WT5-10 was similarly increased in COVID-19 (1.70 ± 0.44 mm) and non-COVID-19 (1.64 ± 0.53 mm) pneumonia compared to controls (1.18 ± 0.34 mm, p < 0.001). Arterial phase λHU5-10 was significantly higher in patients with COVID-19 pneumonia (3.09 ± 2.27 HU/keV) than in non-COVID-19 pneumonia (2.18 ± 1.54 HU/keV, p < 0.01) and lung-healthy controls (2.06 ± 1.11 HU/keV, p < 0.01).

Conclusion

Spectral CT shows significant differences in segmental wall thickness and airway contrast enhancement between COVID-19 and non-COVID-19 pneumonia and lung-healthy controls. Airway contrast enhancement may be a feasible measure to detect airway inflammation in pneumonia and neovascularization in COVID-19 pneumonia.

Key Points

Question Is spectral CT airway contrast enhancement a feasible quantitative method to detect airway inflammation or neovascularisation?

Findings Spectral CT shows significant differences in segmental wall thickness and airway contrast enhancement between COVID-19 and non-COVID-19 pneumonia, and lung-healthy controls.

Clinical relevance Spectral CT can be used to assess inflammatory airway diseases such as cystic fibrosis, COPD, asthma and bronchiectasis.

Graphical Abstract